EUVIMEDEUVIMED entdecken
Crossref

High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best?

Abhijat Kitchlu, Anushree C Shirali

Journal of Onco-Nephrology · 2019

DOI: 10.1177/2399369319827305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Onco-Nephrology, 2019. Verfasst von Abhijat Kitchlu und 1 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney-related adverse drug effects from chemotherapeutic agents can cause acute kidney injury that may influence cancer treatment and patient outcomes. Many current chemotherapy drugs are associated with acute kidney injury, including methotrexate which causes dose-dependent tubular injury. In this review, we will focus on the manifestations of kidney disease secondary to methotrexate and discuss management strategies. In particular, we will review the use of high-flux hemodialysis versus glucarpidase for reducing toxic serum levels of methotrexate.

Zitieren

APA

Kitchlu, A., & Shirali, A. C. (2019). High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best?. Journal of Onco-Nephrology. https://doi.org/10.1177/2399369319827305

Vancouver

Kitchlu A, Shirali AC. High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best?. Journal of Onco-Nephrology. 2019. doi:10.1177/2399369319827305

BibTeX
@article{Kitchlu2019,
  author = {Kitchlu, Abhijat and Shirali, Anushree C},
  title = {High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: What’s best?},
  journal = {Journal of Onco-Nephrology},
  year = {2019},
  doi = {10.1177/2399369319827305}
}
Kostenlos starten →